Adoption of a new technology in a Veterans Affairs national formulary system with local implementation: the insulin glargine example.
A study group gathered by the Pharmacy & Therapeutics Society reviewed data on the Department of Veterans Affairs (VA) health care system's implementation of a new technology (insulin glargine) for patients with diabetes. It examined local implementation of VA criteria for nonformulary use of insulin glargine in 21 VA treatment facilities that were surveyed about the issue. The examination found differences in the use of insulin glargine across the 21 treatment facilities and in the approach to implementing the criteria for nonformulary use of insulin glargine used at the individual VA treatment facility level. Differences were identified regarding the respective roles of endocrinologists and PCPs in prescribing insulins, including insulin glargine. The study group urges further short- and long-term research to better understand the utilization, cost, and health outcome implications of the implementation process for the nonformulary criteria. Lessons learned from such research could benefit other health care systems and formulary committees.
Barengolts
Elena I
EI
Endocrinology Section, Veterans Affairs Center for Health Care Strategies, Chicago, USA.
Burke
Brian V
BV
Duckworth
William C
WC
Kaminsky
Robert
R
Miller
Donald R
DR
Swislocki
Arthur L M
AL
D000554:Ambulatory Care Facilities / Q000458:organization & administration / Q000592:standards*; D001292:Attitude to Computers; D019033:Delivery of Health Care, Integrated / Q000592:standards*; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004059:Diffusion of Innovation; D005569:Formularies as Topic; D006302:Health Services Research; D006787:Hospitals, Veterans / Q000458:organization & administration / Q000592:standards*; D006801:Humans; D007004:Hypoglycemic Agents / Q000600:supply & distribution / Q000627:therapeutic use*; D007328:Insulin / Q000031:analogs & derivatives* / Q000600:supply & distribution / Q000627:therapeutic use; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D007407:Interviews as Topic; D009936:Organizational Innovation; D010606:Pharmacy and Therapeutics Committee; D014481:United States; D014493:United States Department of Veterans Affairs
D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine